STING1 and neoplasm: To investigate the therapeutic efficacy of the cooperative cGAS-STING nanoagonist in vivo, we constructed immunocompetent 4T1-luc tumor-bearing mice, which is a well-established animal tumor model with poor immunogenicity and low response rate to existing immunotherapeutic modalities48.